Millennium Management LLC Boosts Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Millennium Management LLC increased its stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 87.1% during the 2nd quarter, Holdings Channel.com reports. The fund owned 4,346,151 shares of the company’s stock after purchasing an additional 2,023,707 shares during the quarter. Millennium Management LLC’s holdings in Takeda Pharmaceutical were worth $56,239,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Bleakley Financial Group LLC lifted its holdings in shares of Takeda Pharmaceutical by 19.1% in the 1st quarter. Bleakley Financial Group LLC now owns 288,535 shares of the company’s stock valued at $4,008,000 after purchasing an additional 46,182 shares during the last quarter. Envestnet Portfolio Solutions Inc. increased its position in Takeda Pharmaceutical by 7.4% during the first quarter. Envestnet Portfolio Solutions Inc. now owns 25,763 shares of the company’s stock worth $358,000 after buying an additional 1,778 shares during the period. Wealth Enhancement Advisory Services LLC lifted its stake in Takeda Pharmaceutical by 0.7% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 130,904 shares of the company’s stock valued at $1,818,000 after buying an additional 857 shares during the last quarter. OLD Mission Capital LLC lifted its stake in Takeda Pharmaceutical by 1,440.9% in the fourth quarter. OLD Mission Capital LLC now owns 1,041,526 shares of the company’s stock valued at $14,863,000 after buying an additional 973,935 shares during the last quarter. Finally, Van ECK Associates Corp grew its position in shares of Takeda Pharmaceutical by 21.1% during the second quarter. Van ECK Associates Corp now owns 2,040,829 shares of the company’s stock worth $26,408,000 after acquiring an additional 356,069 shares during the last quarter. 9.17% of the stock is owned by hedge funds and other institutional investors.

Takeda Pharmaceutical Stock Performance

Shares of Takeda Pharmaceutical stock opened at $14.21 on Tuesday. The stock has a market capitalization of $45.21 billion, a price-to-earnings ratio of 25.84, a PEG ratio of 0.27 and a beta of 0.54. The firm’s fifty day simple moving average is $14.46 and its 200-day simple moving average is $13.75. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.26 and a quick ratio of 0.74. Takeda Pharmaceutical Company Limited has a 12 month low of $12.57 and a 12 month high of $15.47.

Takeda Pharmaceutical (NYSE:TAK) last announced its earnings results on Wednesday, July 31st. The company reported $0.56 EPS for the quarter, beating analysts’ consensus estimates of $0.37 by $0.19. Takeda Pharmaceutical had a net margin of 6.02% and a return on equity of 10.11%. The business had revenue of $7.75 billion during the quarter. As a group, equities analysts forecast that Takeda Pharmaceutical Company Limited will post 1.63 earnings per share for the current year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.